Island Pharmaceuticals (ILA) Stock Price, News & Analysis

Company Overview

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$25.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:ILA
• CIK: N/A
• Web: www.islandpharmaceuticals.com
• Phone: 61 3 7036 7675
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$2.86 million
• Net Margins: -368.61%
• Pretax Margin: N/A
• Return on Equity: -265.63%
• Return on Assets: -77.59%

Debt

• Debt-to-Equity Ratio: 27.78
• Current Ratio: 2.45
• Quick Ratio: 8.28

Sales & Book Value

• Annual Sales: A$1.25 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,890,000
• Free Float: N/A
• Market Cap: A$25.60 million
• Optionable: Not Optionable
• Beta: 0.40